Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kellie McIntyre

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Expert Opinion on Investigational Drugs|January 28, 2023
Omaveloxolone: an activator of Nrf2 for the treatment of Friedreich ataxiaVictoria Profeta, Kellie McIntyre, McKenzie Wells, et al.
Neurodegenerative Disease Management|June 29, 2022
Friedreich ataxia: clinical features and new developmentsMedina Keita, Kellie McIntyre, Layne N Rodden, et al.
Annals of Clinical and Translational Neurology|June 19, 2023
Retinal hypoplasia and degeneration result in vision loss in Friedreich ataxiaLayne N Rodden, Kellie McIntyre, Medina Keita, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Expert Opinion on Investigational Drugs|January 28, 2023
Omaveloxolone: an activator of Nrf2 for the treatment of Friedreich ataxiaVictoria Profeta, Kellie McIntyre, McKenzie Wells, et al.
Neurodegenerative Disease Management|June 29, 2022
Friedreich ataxia: clinical features and new developmentsMedina Keita, Kellie McIntyre, Layne N Rodden, et al.
Annals of Clinical and Translational Neurology|June 19, 2023
Retinal hypoplasia and degeneration result in vision loss in Friedreich ataxiaLayne N Rodden, Kellie McIntyre, Medina Keita, et al.
Pageof 1